PET Imaging in Recurrent Medullary Thyroid Carcinoma

Abstract EN

Purpose.

To perform an overview about the role of positron emission tomography (PET) or PET/computed tomography (PET/CT) using different radiopharmaceuticals in recurrent medullary thyroid carcinoma (MTC) based on biochemical findings (increased tumor marker levels after primary surgery).

Methods.

A comprehensive literature search of studies published in PubMed/MEDLINE, Scopus, and Embase databases through February 2012 regarding PET or PET/CT in patients with recurrent MTC was performed.

Results.

Twenty-nine studies comprising 714 patients with suspected recurrent MTC were retrieved.

Twenty-seven articles evaluated the role of fluorine-18-fluorodeoxyglucose (FDG) PET or PET/CT in recurrent MTC with conflicting results.

Diagnostic accuracy of FDG-PET and PET/CT increased in MTC patients with higher calcitonin and carcinoembryonic antigen values, suggesting that these imaging methods could be very useful in patients with more advanced and aggressive disease.

Eight articles evaluated the role of fluorine-18-dihydroxyphenylalanine (FDOPA) PET or PET/CT in recurrent MTC reporting promising results.

Overall, FDOPA seems to be superior but complementary compared to FDG in detecting recurrent MTC.

Few studies evaluating other PET tracers are also discussed.

Conclusions.

PET radiopharmaceuticals reflect different metabolic pathways in MTC.

FDOPA seems to be the most useful PET tracer in detecting recurrent MTC based on rising levels of tumor markers.

FDG may complement FDOPA in patients with more aggressive MTC.